Appili Therapeutics (Appili Therapeutics) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Appili Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

Appili Therapeutics ROCE % Historical Data

The historical data trend for Appili Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics ROCE % Chart

Appili Therapeutics Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-75.12

-69.63

-126.59

-305.27

-854.79

Appili Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-809.99	-12,888.00	-	-	-

Appili Therapeutics ROCE % Calculation

Appili Therapeutics's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-5.928	/	( ( (6.542 - 5.268)	+	(2.289 - 2.176) )	/ 2 )
	=	-5.928	/	( (1.274	+	0.113)	/ 2 )
	=	-5.928	/	0.6935
	=	-854.79 %

Appili Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	0.872	/	( ( (1.447 - 2.962)	+	(1.467 - 3.137) )	/ 2 )
	=	0.872	/	( ( -1.515	+	-1.67 )	/ 2 )
	=	0.872	/	-1.5925
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Appili Therapeutics (OTCPK:APLIF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Appili Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Appili Therapeutics (Appili Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

APLI:Canada

Address

1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8

Website

https://www.appilitherapeutics.com

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.